Patients treating breast cancer face the risk of purchasing a fake version of Phesgo 600mg injectable solution originally produced by Roche, a global healthcare company.
The National Agency for Food and Drugs Administration and Control (NAFDAC) raised the alarm last week, urging healthcare provid
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
